Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Monday, March 30, 2026The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily ...

Chicago, IL – March 31, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Amgen’s (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen , Apogee Therapeutics and Gilead Sciences . Claim 30% Off TipRanks Premium. Unlock hedge fu ...

Amgen Inc. (NASDAQ:AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings. The firm has reached a critical price level. This is why it is our Stock of ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for ...

Opportunities in the anti-cancer mAbs market include growth in personalized cancer medicine, expansion of biosimilar mAbs, ...